Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EPEG, a new antineoplastic epipodophyllotoxin.

P J Creaven, L M Allen

    Clinical Pharmacology and Therapeutics
    |August 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Testing spatial working memory in pigs using an automated T-maze.

    Oxford open neuroscience·2024
    Same author

    Medical and gynecological comorbidities in adult women with Turner syndrome: our multidisciplinary clinic experience.

    Climacteric : the journal of the International Menopause Society·2019
    Same author

    Retrospective review of cerebral mycotic aneurysms in 26 patients: focus on treatment in strongly immunocompromised patients with a brief literature review.

    AJNR. American journal of neuroradiology·2012
    Same author

    Menstrual suppression for adolescents with developmental disabilities.

    Journal of pediatric and adolescent gynecology·2009
    Same author

    Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.

    Journal of chemotherapy (Florence, Italy)·2006
    Same author

    S-phase modulation by irinotecan: pilot studies in advanced solid tumors.

    Cancer chemotherapy and pharmacology·2005
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

    Clinical pharmacology and therapeutics·2026
    See all related articles

    This study investigated the pharmacokinetics of epipodophyllotoxin EPEG in cancer patients. Results show biphasic plasma decay and significant renal excretion of unchanged EPEG, suggesting its elimination involves both kidney function and metabolism.

    Area of Science:

    • Pharmacology
    • Oncology
    • Drug Metabolism

    Background:

    • Epipodophyllotoxin derivatives are a class of antineoplastic agents.
    • Understanding the pharmacokinetic profile of novel agents like EPEG is crucial for optimizing cancer therapy.

    Purpose of the Study:

    • To characterize the pharmacokinetic properties of a new epipodophyllotoxin, EPEG, in cancer patients.
    • To determine the routes of elimination and distribution of EPEG in the body.

    Main Methods:

    • Nine patients received intravenous infusions of tritium-labeled EPEG at two dose levels (220 and 290 mg/sq m).
    • Plasma concentrations were measured over time to determine decay kinetics.
    • Urinary recovery and cerebrospinal fluid penetration were assessed.

    Related Experiment Videos

    Main Results:

    • EPEG exhibited biphasic plasma decay with dose-dependent parameters.
    • The mean volume of distribution was approximately 32.07% of body weight.
    • Urinary recovery accounted for 43.5% of the dose, with 66.8% being unchanged drug; cerebrospinal fluid penetration was limited.

    Conclusions:

    • Renal excretion and metabolism are key pathways for EPEG elimination.
    • The pharmacokinetic data provide a basis for further clinical development of EPEG as an antineoplastic agent.